Adjudicated CN SSE

Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances

Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.

CASE PROFILE & BENCHMARKS
  • Target Issuer: Kangmei Pharmaceutical Co., Ltd. (CN).
  • Fraud Period: January 1, 2019 to December 31, 2021.
  • Reported Overstatement: $4.4B.
  • Total Fines & Penalties: $350.0M.
  • Maximum Incarceration: No prison sentence.
  • Independent Auditor: Ernst & Young LLP.
  • Primary Schemes: fictitious cash and assets.
  • Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $4.4B USD reported
TOTAL PENALTIES $350.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2021 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR China Securities Regulatory Commission (CSRC) CN

FORENSIC ACCOUNTING AUTOPSY & MECHANICS

COMPREHENSIVE MULTI-PHASE INVESTIGATION
Forensic Dimension Investigative Finding & Evidentiary Record
Executive Motive & Pressure Kangmei Pharmaceutical was a flagship blue-chip constituent of China's CSI 300 index, celebrated for rapid growth in traditional Chinese medicine supply chains. To sustain its valuation and fund related-party real estate ventures controlled by founder Ma Xingtian, the company systematically fabricated revenues, inventory, and cash balances from 2016 through 2018.
Auditor Blind Spots & Breakdown GP Certified Public Accountants issued clean audit opinions across multiple years without independently reconciling bank confirmation responses against central clearing records, failing to question why a company claiming $5B in idle cash needed to borrow billions at high interest rates.
Detection Catalyst & Unraveling Following a CSRC investigation triggered by debt repayment stress and 'cash-rich yet borrowing-heavy' anomalies, Kangmei stunned markets in April 2019 by wiping 30B yuan of cash off its balance sheet. In 2021, a Guangzhou court issued China's first landmark securities class-action judgment of 2.46B yuan and sentenced Ma Xingtian to 12 years in prison.
Screening & Prevention Takeaway The Cash-vs-Debt Paradox: Whenever an issuer reports massive idle cash balances earning low deposit yields while simultaneously issuing high-yield bonds or short-term commercial paper, the reported cash is often encumbered, pledged, or completely fictitious.
Statutory Violations & Charges
PRC Securities Law Article 63 & Criminal Law Article 161 (False Financial Reporting) Guangzhou Intermediate People's Court Landmark Class-Action Verdict (2.46B Yuan) CSRC Lifetime Securities Market Ban (Ma Xingtian)

STEP-BY-STEP SCHEME EXECUTION MECHANICS

4 PHASES
Phase Execution Step & General Ledger Mechanics
Step 01 1. Finance staff forged bank deposit slips, electronic transfer receipts, and bank statements to inflate reported cash and bank balances by 29.9 billion yuan ($4.4B USD).
Step 02 2. Kangmei simultaneously fabricated 20.6 billion yuan in fictitious sales revenue and overstated fixed assets and construction-in-progress.
Step 03 3. Funds raised from bond and equity markets were secretly routed to related-party entities controlled by Ma Xingtian for real estate and stock speculation.
Step 04 4. When forced to restate in April 2019, management astonishingly attributed the missing 30 billion yuan in cash to an 'accounting clerical error'.

FORENSIC JOURNAL ENTRIES & T-ACCOUNT DISTORTIONS

GENERAL LEDGER TRANSACTIONS
Period Debit (+) Account Debit ($) Credit (-) Account Credit ($) Forensic Intent & Financial Statement Distortion
2016-2018 (Forged Bank Cash & Revenue Inflation) Cash and Bank Balances (Fictitious) $4.4B Sales Revenue & Related-Party Clearing Accounts $4.4B
Intent: Fabricate liquid cash reserves on the balance sheet while diverting capital to insider real estate projects.
Distortion: Overstated cash by nearly 30B yuan while simultaneously issuing expensive short-term commercial paper.
Taxonomy Applicable Scheme Classifications
Correlated Schemes

CHARGED RESPONDENTS & OUTCOMES

1 NAMED PARTIES
Respondent Role Disposition & Judicial Outcome Prison Civil Penalty O&D Bar
Kangmei Pharmaceutical Co., Ltd. ISSUER Enforcement order and financial sanctions imposed. None $350.0M No

RED FLAGS OBSERVED PRIOR TO DISCOVERY

1 EARLY WARNING INDICATORS
Red Flag Indicator Period Observed Observed Forensic Anomaly Diagnostic View
CASH FLOW TO NET INCOME DIVERGENCE 2019 Operating cash flow severely diverged from reported earnings Inspect Metric →

ENFORCEMENT ACTIONS & PRIMARY DOCKETS

PRIMARY SOURCE CITATIONS
Filing Date Type & Docket ID Enforcement Order & Regulatory Findings Disposition Primary Record
September 20, 2021
foreign regulator
ENF-2019-kangmei-pharma
Enforcement Action: Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances
Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.
Securities & Corporate Law Compliance
admitted Docket Record ↗

TIMELINE OF EVENTS

2 CHRONOLOGICAL MILESTONES
Date Event Category Chronological Forensic Milestone
June 1, 2019 MISSTATEMENT Material accounting irregularities commenced.
September 20, 2021 ENFORCEMENT Regulators commenced formal proceedings.